Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review
Authors
Keywords
-
Journal
Dermatology and Therapy
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-11-04
DOI
10.1007/s13555-023-01054-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis
- (2023) Martin Kolb et al. European Respiratory Review
- A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring
- (2023) Christeen Samuel et al. Dermatology and Therapy
- Roflumilast-Mediated Phosphodiesterase 4D Inhibition Reverses Diabetes-Associated Cardiac Dysfunction and Remodeling: Effects Beyond Glucose Lowering
- (2022) Rui Xu et al. DIABETES
- Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis
- (2022) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases
- (2022) Hideyuki Ujiie et al. Frontiers in Medicine
- Risk of melanoma and nonmelanoma skin cancer with immunosuppressants Part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors
- (2022) Margaret Ann Kreher et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Pharmacology of orismilast, a potent and selective PDE4 inhibitor
- (2022) Jonathan I. Silverberg et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial
- (2021) Elizabeth M. Berry-Kravis et al. NATURE MEDICINE
- The Molecular Biology of Phosphodiesterase 4 Enzymes as Pharmacological Targets: An Interplay of Isoforms, Conformational States, and Inhibitors
- (2021) Dean Paes et al. PHARMACOLOGICAL REVIEWS
- Apremilast effectively inhibits TNFα‐induced vascular inflammation in human endothelial cells
- (2021) M. Otto et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Quantifying Patient Preferences for Systemic Atopic Dermatitis Treatments Using a Discrete-Choice Experiment
- (2020) Marco Boeri et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders
- (2019) Mark E. Gurney et al. JOURNAL OF MEDICINAL CHEMISTRY
- Apremilast Normalizes Gene Expression of Inflammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in Mice
- (2019) Peter H. Schafer et al. Drugs in research & development
- Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex
- (2016) Peter H. Schafer et al. CELLULAR SIGNALLING
- Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
- (2015) C. Paul et al. BRITISH JOURNAL OF DERMATOLOGY
- Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
- (2015) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Drug-induced secretory diarrhea: A role for CFTR
- (2015) Changsuk Moon et al. PHARMACOLOGICAL RESEARCH
- Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity
- (2014) P.H. Schafer et al. CELLULAR SIGNALLING
- Cyclic AMP compartments and signaling specificity: Role of cyclic nucleotide phosphodiesterases
- (2013) Marco Conti et al. JOURNAL OF GENERAL PHYSIOLOGY
- Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease
- (2011) Klaus F. Rabe BRITISH JOURNAL OF PHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search